Codexis to Report Second Quarter 2024 Financial Results on August 8
Codexis (NASDAQ: CDXS), a leading enzyme engineering company, has announced it will release its second quarter 2024 financial results on Thursday, August 8, 2024, after market close. The company will host a conference call and webcast at 4:30 pm Eastern Time to discuss the results and provide a business update. Investors can access the live webcast on the Codexis Investor Relations website, where it will be archived for at least 90 days. For those preferring to join by phone, the live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A 48-hour telephone replay will also be available.
- None.
- None.
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update.
Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for at least 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.
About Codexis
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit www.codexis.com.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com
Media Contact
Lauren Musto
(650) 421-8205
media@codexis.com
FAQ
When will Codexis (CDXS) report its Q2 2024 financial results?
How can investors access Codexis' (CDXS) Q2 2024 earnings call?
Will there be a replay available for Codexis' (CDXS) Q2 2024 earnings call?
Where can I find the archived webcast of Codexis' (CDXS) Q2 2024 earnings call?
